Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the North and South of Europe
Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the North and South of Europe
复制标题
DOI：
10.1161/01.atv.0000015445.22243.f4
复制
发表时间：
2002-05-01
影响因子：
8.7
通讯作者：
Humphries, SE
中科院分区：
文献类型：
--
作者：
Juhan-Vague, I;Morange, PE;Humphries, SE
凝血酶可激活的纤维蛋白溶解抑制剂（TAFI）是最近描述的纤维蛋白溶解抑制剂，其减少纤溶酶原与纤维蛋白表面的结合。血浆TAFI浓度几乎完全由遗传决定。我们研究了血浆TAFI水平和位于TAFI基因的多态性是否可以构成心肌梗死（MI）的危险标志物。用ELISA法测定血浆TAFI抗原（Ag）水平，并在欧洲一项大型病例对照研究中确定2个TAFI基因多态性（3'非翻译区的Ala147Thr和C+1542G）。这项研究比较了598名MI后3至6个月的男性与653名来自北欧（瑞典斯德哥尔摩和英国伦敦）和南欧（法国马赛和意大利圣乔瓦尼罗通多）的年龄匹配对照。TAFI Ag值高于第90百分位数与MI风险显著降低相关（比值比0.55，P
The thrombin-activatable fibrinolysis inhibitor (TAFI) is a recently described inhibitor of fibrinolysis that decreases plasminogen binding to the fibrin surface. The plasma TAFI concentration is almost entirely genetically determined. We investigated whether plasma TAFI levels and polymorphisms located in the TAFI gone could constitute risk markers of myocardial infarction (MI). Plasma TAFI antigen (Ag) levels were assayed by ELISA and 2 TAFI gene polymorphisms (Ala147Thr and C+1542G in the 3' untranslated region) were determined in a large European case-control study. This study compared 598 men recruited 3 to 6 months after MI with 653 age-matched controls from North Europe (Stockholm, Sweden, and London, England) and South Europe (Marseilles, France, and San Giovanni Rotondo, Italy). A TAFI Ag value above the 90th percentile was associated with a significantly lower risk of MI (odds ratio 0.55, P